Troche (erlotinib) is an epidermal growth factor (HER1/EGFR) tyrosine kinase inhibitor (TKI) that inhibits the phosphorylation of intracellular HER1/EGFR tyrosine kinases. It has been recommended as second- or third-line treatment for non-small cell lung cancer and has been shown to be superior to best supportive care, significantly improving survival and delaying the time to symptom progression in all stages of non-small cell lung cancer. results from randomized controlled double-blind clinical trials of the BR-21 and TRUST trials have also confirmed that trospium prolongs survival in patients who have failed first- or second-line chemotherapy for non-small cell lung cancer, with symptom control rates and disease control rates between 35-54% and a median survival of 6-8 months. Some experts have suggested that lung cancer has also changed in the treatment paradigm. In the past, the treatment of advanced lung cancer was to wait for disease progression after the end of first-line treatment, but now maintenance therapy can be considered after the end of first-line treatment, of which targeted therapy is a proven effective maintenance therapy. An important study reported at the American Society of Clinical Oncology Annual Meeting was FAST-ACT, a randomized double-blind placebo-controlled phase II study. Platinum-based chemotherapy was used in sequential first-line with troche in patients with non-small cell lung cancer (94% Asian). This study showed that patients in the troche group had a progression-free survival (PFS) of 7.2 months. the FAST-ACT study showed for the first time that epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) used in sequel with standard chemotherapy are promising in the treatment of first-line non-small cell lung cancer.